This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 21, 2019
Steriline’s Robotic Nest Filling Machine Enhances Drug R&D
Author(s)BioPharm International Editors
The company showcased its compact robotic nest filling machine at CPhI Worldwide 2019 on Nov.–7 in Frankfurt, Germany.
Advertisement
Steriline, a European manufacturer of complete lines for aseptic processing of injectable products, presented its Robotic Nest Filling Machine for Lab (RNFM–LAB), a compact robotic nest filling machine, for the first time outside of Italy at CPhI Worldwide 2019 on Nov. 5–7 in Frankfurt, Germany. The machine, first introduced in April 2019 at Pharmintech in Bologna, Italy, was especially designed for R&D purposes, according to the company.
The RNFM–LAB can be equipped with one or two dosing pumps and a stoppering system. It also provides manual tub loading/unloading and moves with a speed up to approximately 1000 pieces/h. It is exclusively intended for the research and development of new injectable drugs in nest (via syringes, cartridges, or vials) and it is able to perform all standard robotic filling operations.
“Our client request for this kind of robotic machine came from the need to define and maximize a new manufacturing process,” said Federico Fumagalli, chief commercial officer at Steriline, in a Nov 5, 2019 company press release. “[R]obotics was the perfect solution, in fact, to get an easier format change with just some software adjustments”.
“We always developed machines for production so far, since [R&D] is a very challenging sector and business. Companies ask for a support in this field just when they actually have something new to develop. In this case, our client chose us as their perfect partner to design and project together a new machine which could meet all their needs and satisfy all their requirements,” added Fumagalli in the press release.
In addition to CPhI Worldwide, the company is also exhibiting the machine at Pharmtech 2019 in Moscow, Russia, which runs Nov. 19–22, and at CPhI & P-MEC in Delhi, India, which runs Nov. 26–28.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5